Previous 10 | Next 10 |
FDA agrees to the submission of an NDA for poziotinib for non-small cell lung cancer (NSCLC) in previously treated patients with HER2 exon 20 insertion mutations, NDA submission planned for 2021 Cohort 3 of the ZENITH20 clinical trial, which enrolled first-line NSCLC patients ...
NEW YORK, Dec. 17, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced the appointment of Dr. Jeffrey Vacirca to its ...
Spectrum Pharmaceuticals (NasdaqGS: SPPI) a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the appointment of Nora Brennan to its Board of Directors. Ms. Brennan fills a vacancy left by Ms. Elizabeth Czerepak, who retired from the Board effec...
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that three posters highlighting its drug development pipeline would be presented at the upcoming San Antonio Breast Cancer Conference (SABCS) to be he...
Spectrum Pharma is down due to two resolvable issues. If the Rolontis PDUFA issue is resolved, the stock may shoot up. The Poziotinib situation works as a nice backup to the story. For further details see: Spectrum Pharma Is Down But Not Out
Spectrum is a $550m market cap biotech developing 2 drugs that are close to securing FDA approval but are subject to frustrating delays. A PDUFA date for Severe Neutropenia treatment Rolontis has been delayed until the FDA can complete a visit to Spectrum's partner Hanmi's South Korea...
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that management will present an overview of the company's business strategy and development-stage programs at two upcoming virtual investor conference...
Image source: The Motley Fool. Spectrum Pharmaceuticals Inc (NASDAQ: SPPI) Q3 2020 Earnings Call Nov 4, 2020 , 4:30 p.m. ET Operator Continue reading For further details see: Spectrum Pharmaceuticals Inc (SPPI) Q3 2020 Earnings Call Trans...
Spectrum Pharmaceuticals, Inc. (SPPI) Q3 2020 Earnings Conference Call November 4, 2020 4:30 P.M. ET Company Participants Kurt Gustafson - Chief Financial Officer Joe Turgeon - President and Chief Executive Officer François Lebel - Chief Medical Officer Tom Riga - Chief Operating Officer...
Spectrum Pharmaceuticals (SPPI): Q3 Non-GAAP EPS of -$0.27; GAAP EPS of -$0.37 misses by $0.02.The company ended the quarter with cash, cash equivalents, and marketable securities of $198.3 million.Press Release For further details see: Spectrum Pharmaceuticals EPS misses by $0.02
News, Short Squeeze, Breakout and More Instantly...
Spectrum Pharmaceuticals Inc. Company Name:
SPPI Stock Symbol:
NASDAQ Market:
Spectrum Pharmaceuticals Inc. Website:
New York, New York--(Newsfile Corp. - December 14, 2022) - Levi & Korsinsky, LLP notifies investors in Spectrum Pharmaceuticals, Inc. ("Spectrum" or the "Company") (NASDAQ: SPPI) of a class action securities lawsuit. The lawsuit on behalf of Spectrum investors has been commenced in the the...
NEW YORK, NY / ACCESSWIRE / December 12, 2022 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Spectrum Pharmaceuticals, Inc. ("Spectrum" or the "Company") (NASDAQ:SPPI) and reminds investors of the February 3, 2023 deadline to seek th...
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Spectrum To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - December 7, 2022) - Faruqi & Faruqi, LLP, a leading national securities law firm, i...